Treatment Outcomes and Predictors of Outcome in Multidrug Resistance Tuberculosis (MDR-TB) Cohort of Patients in Addis Ababa, Ethiopia

Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study

“…The current study found a 77.12% (95% CI = 73.0–81.5) MDR/RR-TB TSR, which is in agreement with the 75.7% national TSR report (from 2009 to 2019) by Habteyes Tola. 21 Other retrospective studies conducted in Addis Ababa (2011–2016) 26 and Southern-Ethiopia (2014–2019) 27 also reported similar findings, 76.9% and 76.32%, respectively. However, according to a review paper published in 2020, the overall pooled TSR in Ethiopia was 63.82%, which was less than the current report.…”

“…A study conducted from a teaching and referral hospital in Wolayta Sodo, Ethiopia, reported similar findings. 39 However, studies in Ethiopia and abroad reported that undernutrition, 31 , 33 HIV infection, 21 , 26 and history of anti-TB drug use 40 were risk factors for unsuccessful treatment outcomes such as treatment failure and death. In the present study, there were a considerable number of patients with unknown HIV and BMI status, which may have underestimated the frequency of HIV infection and BMI, respectively.…”

Drug-resistance, treatment outcome and their predictors in pulmonary tuberculosis at Yirgalem General Hospital Multidrug-Resistance Tuberculosis treatment initiation center, Sidama Region, South Ethiopia: a Retrospective cohort study

“…Of which 18(9.2%) were died during the treatment course while 27(13.8%) and 6(3.1%) were LTFU and treatment failure respectively. The nding was higher than the national target by 2020 in which only <10% should have unfavorable treatment outcome [3] and aggregated 17.3% unfavorable treatment outcome reported by Molie et al in 2019 [27] in the country and other similar retrospective studies, 23.2% [5] in Addis Ababa and 23.68% [28] in Southern-Ethiopia. The observed discrepancy might be due to sample size variations and socio-demographic and clinical conditions of the participants.…”

“…In 2019 the global burden of multidrug-or rifampicin-resistant TB (MDR/RR-TB) as a share of the number of TB cases remains stable, an estimated 3.3% of new and 18% of previously treated TB cases had MDR/RRTB with a total of 206 030 MDR/RR-TB patients were detected and noti ed, this increased by 10% from 186 883 in 2018 [1,5], global treatment success rate among 177099 patients enrolled for the treatment was recorded as 57% [1] According to federal democratic republic of Ethiopia(FDRE), the incidence rate of RR/MDR-TB cases were estimated to be 2.7% and 14% among new and previously treated cases respectively [6,7]. Eshetie et al reviewed reported, overall prevalence of DR-TB among newly diagnosed and previously treated TB patients to be 2% and 15% respectively in Ethiopia [8].…”

“…The magnitude and extent of drug resistance in TB being monitored [18]. MDR-TB treatment started in 2009 in TB specialized hospitals in Ethiopia and expanded to selected regional hospitals in 2013, under programmatic guidelines for management of DR-TB [5]. The overall epidemiology of DR-TB is not well studied in Ethiopia [19] and few studies have been documented so far as country and study are in particular.…”